Seeing Meningiomas Clearly: How SSTR-Targeted PET Scans Are Changing Diagnosis, Treatment, and Monitoring

Table of Contents

• Key Points
• Understanding Meningiomas: The Most Common Brain Tumor
• Why Conventional Imaging Has Limits
• What Is SSTR-Targeted PET Imaging?
• How This Review Was Conducted
• Detecting Meningiomas with [⁶⁸Ga]Ga-DOTATATE PET
• Using PET to Plan Radiation Therapy More Precisely
• Tracking Residual and Recurrent Tumors After Treatment
• Strengths and Limitations of [⁶⁸Ga]Ga-DOTATATE PET
• The Role of [⁶⁸Ga]Ga-DOTATOC
• The Role of [⁶⁸Ga]Ga-DOTANOC in Difficult Diagnoses
• Theranostics: Seeing and Treating Meningiomas at the Same Time
• Next-Generation Tracers: [¹⁸F]SiTATE
• What This Means for Patients
• What This Review Could Not Prove
• Recommendations and Future Research
• Frequently Asked Questions
• Source Information

Key Points

• SSTR-targeted PET detects meningiomas with 95–100% sensitivity across reviewed studies, often spotting tumor involvement that MRI misses, including bone invasion (98.5% vs 53.7% in one study of 82 patients).
• In one study of 29 patients, PET-guided radiation planning reduced target volume by 84% and cut dose to critical structures by 50% or more, while maintaining complete tumor coverage.
• After apparent complete removal, PET found residual tumor in 41–63% of 37 patients that MRI missed; a negative PET predicts low recurrence risk.
• In a case series of 12 patients, PET changed clinical management in up to 42% of cases by uncovering hidden disease, including subcentimeter and intraosseous lesions.
• Limitations include no standardized SUVmax thresholds (cutoffs 2.3 to >4.0), risk of overtreatment in asymptomatic patients, and undefined optimal timing for surveillance scans.

Understanding Meningiomas: The Most Common Brain Tumor

Meningiomas are tumors that grow from the meninges, the protective membranes that surround the brain and spinal cord. They are remarkably common, accounting for 41.7% of all primary central nervous system (CNS) tumors — meaning they are the most frequently diagnosed primary brain tumor type.

The risk of developing a meningioma rises sharply after age 40. The annual incidence in that age group is 18.69 cases per 100,000 people. Women are affected disproportionately, with an incidence ratio of 2.33 to 1 compared with men.

The World Health Organization (WHO) divides meningiomas into three grades based on their microscopic appearance and biological behavior:

• Grade I (benign): Makes up 80.5% of cases. These tumors grow slowly, show minimal cellular atypia (abnormal cell features), and usually have favorable outcomes after surgical removal.
• Grade II (atypical): Accounts for 17.7% of cases. These tumors show increased cellularity (more densely packed cells), prominent nucleoli (enlarged structures inside the nucleus), and sheet-like growth patterns. They carry a higher risk of recurrence.
• Grade III (anaplastic/malignant): Represents 1.7% of cases. These aggressive tumors feature necrosis (tissue death) and loss of typical meningioma architecture, leading to rapid progression, frequent recurrence, and the potential to metastasize (spread to other parts of the body).

Symptoms depend on tumor size, location, growth rate, and the degree of associated cerebral edema (swelling in the brain). Many meningiomas are discovered incidentally — that is, by chance during scans for unrelated problems. Symptomatic cases typically arise from mass effect (pressure on brain structures), producing headaches, nausea, cognitive changes, or signs of elevated intracranial pressure (pressure inside the skull).

Why Conventional Imaging Has Limits

Early diagnosis is essential for effective treatment, but standard imaging tools have significant shortcomings. MRI provides excellent soft-tissue contrast. However, it cannot reliably distinguish tumor tissue from physiological dural enhancement (normal thickening of the dura, the brain's outer membrane), especially at the skull base and near the cavernous sinus (a area at the base of the brain). MRI also struggles to tell apart post-treatment residual tumor from scar tissue.

Computed tomography (CT) supplements MRI by detecting calcification (calcium deposits) and osseous involvement (tumor spread into bone). Yet CT lacks the soft-tissue resolution needed for precise margin delineation (defining tumor edges).

Even when MRI and CT are combined, these anatomical imaging methods offer limited insight into metabolic activity or biological aggressiveness. Traditional PET scanning with [¹⁸F]-fluorodeoxyglucose (FDG), a tracer that measures glucose use, offers little clinical value in meningioma. Meningiomas have low glucose uptake, and the brain's high cortical background activity creates poor contrast between tumor and normal tissue.

These gaps matter because a meningioma's exact location, extent, and grade drive treatment decisions such as whether to operate, where to aim radiation, and how closely to monitor after therapy.

What Is SSTR-Targeted PET Imaging?

Meningiomas uniformly overexpress somatostatin receptor subtype 2 (SSTR2) — meaning they carry far more of this specific receptor on their surface than normal brain tissue does. That biological difference gives doctors an ideal molecular target for PET imaging.

SSTR-targeted radiotracers are radioactive molecules designed to latch onto SSTR2 receptors. The three most studied gallium-68–labeled tracers are [⁶⁸Ga]Ga-DOTATATE, [⁶⁸Ga]Ga-DOTATOC, and [⁶⁸Ga]Ga-DOTANOC. These agents bind SSTR2 with high affinity — roughly 10-fold higher than conventional scintigraphy (an older nuclear imaging technique) — and undergo receptor-mediated internalization (the cell pulls the tracer inside). The result is superior tumor-to-background contrast, which makes even small or awkwardly located tumors visible.

These tracers are labeled with gallium-68, a positron-emitting radioisotope with a half-life of 68 minutes (the time it takes for half the radioactivity to decay). Gallium-68 is produced through [⁶⁸Ge]/[⁶⁸Ga] generators, which allow hospitals to make the tracer on-site without needing a cyclotron (a particle accelerator used to produce other radioisotopes). That logistics advantage has enabled widespread clinical use.

The purpose of this review was to evaluate how well SSTR-targeted PET works across four areas of meningioma care: diagnosis, treatment planning, surveillance (follow-up monitoring), and theranostics (combining a diagnostic tracer with a therapeutic radioactive drug).

How This Review Was Conducted

The research team performed a literature review, searching PubMed, Google Scholar, Embase, and Web of Science databases from their inception through November 1, 2025. Keywords included "PET," "SSTR," and "meningioma" in various combinations.

Studies evaluating [⁶⁸Ga]Ga-DOTATATE, [⁶⁸Ga]Ga-DOTATOC, [⁶⁸Ga]Ga-DOTANOC, and novel fluorine-18 tracers in meningioma patients were analyzed. Each study was assessed for quality, risk of bias, and its ability to inform the review's objectives. The findings were then synthesized to create an overview of SSTR PET-based imaging in meningioma.

This is a review article, not a new clinical trial. Its conclusions rest on the strength of the underlying studies, which include prospective cohorts, retrospective analyses, and small case series.

Detecting Meningiomas with [⁶⁸Ga]Ga-DOTATATE PET

[⁶⁸Ga]Ga-DOTATATE PET reliably distinguishes tumor tissue from normal tissue. Clinical validation began with evidence that the maximum standardized uptake value (SUVmax) — a number that reflects how intensely a tissue absorbs the tracer — strongly correlates with SSTR2 expression.

In one foundational study by Rachinger and colleagues, 21 patients with 115 tumors were scanned. A SUVmax threshold above 2.3 reliably discriminated tumor from nontumor tissue and correlated with SSTR2 expression. The study also validated PET-guided tissue sampling, in which the scan directs surgeons to the most active tumor regions during an operation.

Overall diagnostic sensitivity across the reviewed studies ranges from 95% to 100%. That means the test rarely misses an actual meningioma. SUVmax also correlates with tumor growth rates, particularly in transosseous meningiomas (tumors that grow through the skull bone). This correlation is independent of WHO grade, which makes [⁶⁸Ga]Ga-DOTATATE PET a functional complement to histopathology (the microscopic examination of tissue).

[⁶⁸Ga]Ga-DOTATATE PET outperforms MRI in anatomically challenging regions. In a study of 13 ambiguous optic pathway lesions (tumors near the nerves carrying vision signals), PET correctly classified 10 of them, outperforming conventional imaging. For osseous involvement (tumor invasion into bone), [⁶⁸Ga]Ga-DOTATATE PET/CT achieved a markedly higher sensitivity than MRI — 98.5% versus 53.7% — with comparable specificity, in a study of 82 patients by Kunz and colleagues. Those results improved both surgical planning and risk assessment.

In post-treatment settings, different SUV measurements serve different purposes. SUVmax provided the highest specificity for recurrent meningioma, while the ratio of SUVmax to the superior sagittal sinus (a major vein at the top of the brain) offered the best balance of sensitivity and specificity.

Using PET to Plan Radiation Therapy More Precisely

Integrating [⁶⁸Ga]Ga-DOTATATE PET into radiation planning improves accuracy where conventional imaging falls short. In a cohort of 25 patients studied by Perlow and colleagues, PET identified additional nonadjacent tumor regions — areas of disease not touching the main tumor — in 28% of cases that MRI had missed. Seven specialists reviewing the scans showed high interobserver agreement (consistency between different doctors interpreting the same images).

In another study of 29 intermediate-risk patients by Mahase and colleagues, PET/MRI-guided planning reduced the mean target volume by 84% (from 71.39 to 11.12 cm³; P < 0.05, a statistically significant result). It also decreased radiation dose to critical structures (nearby healthy tissues such as the optic nerves and brainstem) by 50% or more — all while maintaining complete tumor coverage.

These treatment benefits translate into better patient outcomes. In a study of 85 patients with cavernous sinus meningiomas by Hadi and colleagues, [⁶⁸Ga]Ga-DOTATATE PET-guided radiotherapy achieved striking 5-year progression-free survival (the percentage of patients whose tumor did not grow during five years):

• Surgery only (group A, n = 48): 55.7%
• Surgery plus fractionated stereotactic radiotherapy, or FSRT (group B, n = 25): 100%
• Fractionated stereotactic radiotherapy alone (group C, n = 12): 100%

PET also enabled safer dose escalation. Physicians could deliver a higher radiation dose (54 Gy), the standard unit of absorbed radiation, while reducing ocular (eye) exposure from 45 Gy to 32 Gy. The scan detected meningioma in 23 of 25 patients whose MRI results were equivocal (unclear), and it revealed residual disease in eight patients who were thought to have had a full resection based on MRI alone.

PET can also help stratify patients with more aggressive tumors. In a study of 14 patients with WHO grade III meningiomas, secondary-progressive tumors (those that began as a lower grade and later became malignant) behaved differently from de-novo tumors (those malignant from the start). Secondary-progressive tumors had:

• A higher mutation burden (3.5 versus 1.2 mutations; P = 0.024)
• A trend toward more prior radiation therapy courses (2.4 versus 1.6; P = 0.23)
• Higher cumulative radiation doses (106 versus 68.3 Gy; P = 0.31)
• Lower progression-free survival (4.8 versus 37.7 months; P = 0.004)
• Greater [⁶⁸Ga]Ga-DOTATATE PET SUVmax values (17.1 versus 12.4; P = 0.0021)

The higher tracer uptake in secondary-progressive tumors suggests PET can aid patient stratification and personalized treatment planning. In one study of 17 patients with 18 lesions receiving stereotactic radiosurgery for WHO grade I meningiomas, PET/MRI contouring produced slightly larger gross tumor volumes (GTVs, the visible tumor volume targeted by radiation) than MRI alone — 3.59 versus 3.18 cm³ — though with increased interobserver variability. That finding underscores the need for specialized training in PET-based planning.

There is also evidence that PET can spare patients unnecessary treatment. In a cohort of 48 patients, those without local [⁶⁸Ga]Ga-DOTATATE uptake who did not receive immediate radiation experienced no recurrences. This indicates that PET could inform decisions to safely defer intervention in select patients.

Tracking Residual and Recurrent Tumors After Treatment

PET detects residual or recurrent disease that conventional methods often miss. In 37 patients classified as fully resected according to Simpson grading (a scale that rates how completely a meningioma is surgically removed) and postoperative MRI, [⁶⁸Ga]Ga-DOTATATE PET detected tumor remnants in 41–63% of patients. Many of these remnants were not visible on MRI. This finding challenges the assumption that a Simpson Grade I–II resection plus a clean MRI means no tumor remains.

[⁶⁸Ga]Ga-DOTATATE PET also distinguishes tumor recurrence from treatment-related changes. In a cohort of 20 patients, PET confirmed recurrence in 17 of 20 cases where MRI or clinical findings were ambiguous.

The scan carries prognostic value across tumor grades. In 46 patients with 49 resected WHO grade I meningiomas, a positive postoperative PET predicted a higher recurrence risk and shorter progression-free survival. A negative PET scan, by contrast, was strongly associated with favorable outcomes.

For higher-grade tumors, the benefits persist. In 12 patients with grade II tumors, [⁶⁸Ga]Ga-DOTATATE PET-guided surveillance achieved a 3-year progression-free survival of 75% and an overall survival of 100%. Those results exceed typical outcomes for grade II disease, suggesting some patients could safely forgo adjuvant (additional) therapy based on PET findings.

Functional changes on PET often precede structural changes on MRI. That means PET can detect recurrence or residual tumor activity earlier than conventional imaging, enabling earlier intervention.

Most importantly, PET results change real-world care. In a case series of 12 patients by Hintz and colleagues, [⁶⁸Ga]Ga-DOTATATE PET altered clinical management in up to 42% of cases. The scan led to treatment plan modifications or identified additional lesions — including subcentimeter (less than one centimeter) and intraosseous (inside bone) disease not clearly visible on MRI or CT.

Strengths and Limitations of [⁶⁸Ga]Ga-DOTATATE PET

[⁶⁸Ga]Ga-DOTATATE PET's main strength is its ability to improve lesion detection in complex anatomical regions and at osseous (bone) sites. PET-guided radiation therapy enables significant target volume reduction and better sparing of critical structures, but successful implementation requires dedicated training and standardized protocols to reduce interobserver variability (differences in how doctors interpret images).

For active surveillance, the scan surpasses conventional imaging by identifying residual and recurrent disease while offering prognostic information. A negative scan correlates with a low risk of recurrence, giving patients and doctors valuable reassurance.

Several challenges remain. The optimal timing and frequency of follow-up scans are not well-defined. The clinical significance of positive findings in asymptomatic patients (people without symptoms) is also unclear — a positive scan does not always mean treatment is needed. There is a real risk of overtreatment if every PET finding triggers aggressive therapy.

Technical limitations include:

• Nonspecific SSTR uptake — other tissues in the body that express SSTR2 can also light up on the scan
• Lower spatial resolution compared with MRI, meaning very small lesions can be missed
• No standardized uptake value thresholds — published cutoffs range from 2.3 to greater than 4.0, which limits how easily results can be compared across institutions

These issues highlight the need for standardized interpretation criteria and further research to optimize clinical use while minimizing overtreatment.

The Role of [⁶⁸Ga]Ga-DOTATOC

[⁶⁸Ga]Ga-DOTATOC is the second major tracer in this family, and its clinical utility was first demonstrated in just three patients with eight meningiomas. In that pilot study by Henze and colleagues, all meningiomas showed high tracer uptake and clear visualization even beneath the skull base. The superior contrast came from a high tumor-to-background ratio and favorable pharmacokinetics — the tracer cleared rapidly from the blood, with half-lives of 3.5 and 63 minutes.

Larger studies confirmed these early findings. In a study of 51 patients, tracer uptake measured by SUVmax correlated strongly with the expression of three somatostatin receptor subtypes:

• SSTR2A: P < 0.001, r² = 0.669 (the strongest correlation)
• SSTR2B: P = 0.001, r² = 0.393
• SSTR5: P = 0.012, r² = 0.235

A radiomic model based on diffusion-weighted MRI (an MRI technique that measures water movement in tissue) successfully reproduced PET-derived SUVmax values, supporting the feasibility of integrated imaging approaches.

Comparative studies highlight [⁶⁸Ga]Ga-DOTATOC PET's diagnostic advantage in challenging locations. In a cohort of 190 patients studied by Afshar-Oromieh and colleagues, the tracer demonstrated improved sensitivity at the falx cerebri (the membrane fold between the brain's two hemispheres) and skull base — anatomical regions where MRI often underperforms.

In a study of 57 patients with 112 tumors by Einhellig and colleagues, PET/MRI achieved a sensitivity of 99% and a specificity of 83%. MRI alone, by comparison, achieved 95% sensitivity and 88% specificity. PET/MRI was particularly valuable for small or complex lesions, though it requires a specialized hybrid scanner and carries higher cost.

This tracer also improves radiation planning. In a study of 48 patients with skull base tumors by Graf and colleagues, PET/CT increased the gross tumor volume by about 1.5 cm³ while reducing the total irradiated volume by 4.5 cm³ compared with MRI/CT alone. In other words, the radiation beam covered the true tumor more precisely and spared more healthy tissue.

For post-resection surveillance, Bashir and colleagues studied 37 patients and found that [⁶⁸Ga]Ga-DOTATOC PET had a sensitivity of 90%, a specificity of 92%, and a diagnostic accuracy of 90% for residual disease, compared with 3-month MRI read using RANO (Response Assessment in Neuro-Oncology) criteria. That study used a high-resolution research tomograph, a scanner not widely available in routine practice.

Proof-of-concept work includes a single-patient study by Thorwarth and colleagues, which demonstrated the first simultaneous PET/MRI for intensity-modulated radiation therapy planning. The approach improved visualization of infiltrative growth (tumor spreading into surrounding tissue) with finer voxel resolution (smaller three-dimensional image units), showing potential dosimetric consequences. [⁶⁸Ga]Ga-DOTATOC PET has also proven useful in rarer scenarios, such as optic nerve sheath meningiomas, where it improves tumor delineation and target volume planning for intensity-modulated radiotherapy, especially in recurrent or skull base tumors.

The Role of [⁶⁸Ga]Ga-DOTANOC in Difficult Diagnoses

[⁶⁸Ga]Ga-DOTANOC has a broader SSTR affinity profile than DOTATATE, which can be both an advantage and a drawback. In a study of 42 patients by Purandare and colleagues, the median SUVmax was significantly higher in meningiomas than in dural metastases (cancers that have spread to the dura from elsewhere) — 12.7 versus 6.0, with P = 0.001. This difference enabled doctors to tell the two conditions apart on a PET scan.

The substantial overlap between the two groups in individual patients, however, limits certainty in any single case. The broader SSTR affinity of DOTANOC also reduces its specificity compared with DOTATATE, and this tracer is less extensively validated in the meningioma literature. It remains a useful option, particularly when the diagnosis is uncertain, but the evidence base is thinner.

Theranostics: Seeing and Treating Meningiomas at the Same Time

One of the most exciting developments in this field is the theranostic paradigm — using the same molecular target to both image a tumor and deliver therapy. The diagnostic tracers reveal where SSTR2 is present; then a therapeutic partner, [¹⁷⁷Lu]Lu-DOTATATE, carries a radioactive payload (lutetium-177) directly to those same receptors.

This approach, called peptide receptor radionuclide therapy (PRRT), delivers targeted radiation from inside the tumor cells. Minczeles and colleagues treated 15 patients with progressive, treatment-refractory meningiomas and achieved disease stabilization in 60–80% of cases. Severi and colleagues followed 42 patients over the long term and demonstrated both efficacy and an acceptable toxicity (side effect) profile in refractory meningiomas.

These results matter for patients with recurrent or progressive disease who have exhausted surgery and radiation options. PRRT offers a systemic therapy that delivers radiation to the tumor, but because meningiomas can lie close to the optic apparatus, brainstem and cranial nerves, the effect on nearby normal tissue remains an open question. The reviewed studies were small, and one included a heavily pretreated population, so the durability of responses and long-term toxicity data remain areas of active investigation.

Next-Generation Tracers: [¹⁸F]SiTATE

While gallium-68 tracers work well, they require on-site generator production and have time constraints due to the short 68-minute half-life. Next-generation fluorine-18 tracers, particularly [¹⁸F]SiTATE, aim to solve these problems.

Unterrainer and colleagues reported the first clinical experience with [¹⁸F]SiTATE in 107 patients with 292 tumors. The tracer showed high tumor uptake and excellent image quality, with automated production offering economic and logistical advantages over gallium-68 tracers. Fluorine-18 has a longer half-life (about 110 minutes), which allows centralized production and distribution to multiple hospitals.

These tracers promise improved logistics and cost-effectiveness. The evidence so far is preliminary, however, and larger validation studies are needed. No direct head-to-head comparison with gallium-68 tracers has been published yet.

What This Means for Patients

SSTR-targeted PET represents a genuine advance for meningioma patients. The take-home points, expressed as absolute numbers, are:

• Better detection: PET finds meningiomas with 95–100% sensitivity, and it detects bone involvement that MRI misses in roughly 45 out of every 100 such cases (98.5% versus 53.7% in one study of 82 patients).
• More precise radiation: In one study, PET-guided planning shrank the radiation target from 71.39 to 11.12 cm³ — an 84% reduction — while cutting dose to healthy structures by at least half.
• Better outcomes: In 85 patients with cavernous sinus meningiomas, adding PET-guided radiotherapy to surgery raised 5-year progression-free survival from 55.7% to 100%.
• Honest surveillance: After apparent complete removal, PET finds residual tumor in 41–63% of patients that MRI missed. A negative PET predicts a low recurrence risk.
• Real treatment changes: PET changed management in up to 42% of cases by uncovering hidden disease.

For a patient facing a new diagnosis, PET can clarify whether the tumor has invaded bone or wrapped around critical structures, which directly influences whether surgery is feasible. For a patient planning radiation, PET can make the treatment both more effective and safer. For a patient who has finished treatment, PET can distinguish scar tissue from recurrence and may guide how often follow-up scans are needed.

What This Review Could Not Prove

Several limitations affect confidence in these findings. Many of the underlying studies were retrospective (looking back at medical records) rather than prospective (following patients forward in time), which introduces potential selection bias. Sample sizes were often small — several key studies included fewer than 50 patients, and one was a single-patient case report.

Technical heterogeneity is a major issue. Acquisition protocols varied across institutions, and there is no universally accepted SUVmax threshold; published cutoffs range from 2.3 to greater than 4.0. This variation limits how directly results from different centers can be compared.

The clinical significance of PET-positive findings in asymptomatic patients is unresolved. Some studies suggest that PET findings may lead to overtreatment if they trigger aggressive therapy without clear evidence of benefit. The optimal timing and frequency of surveillance PET scans also remain undefined.

Additionally, some imaging results came from hybrid PET/MRI scanners or high-resolution research tomographs that are not widely available in routine clinical practice. Cost and availability constraints therefore limit how quickly these advances can reach all patients.

Recommendations and Future Research

Based on this review, physicians and patients should consider the following when making decisions about meningioma care:

1. Ask whether SSTR-targeted PET is available when conventional MRI findings are ambiguous — particularly for tumors at the skull base, in the cavernous sinus, or along the optic pathway, and when bone involvement is suspected.
2. For patients planning radiation therapy, request a discussion of whether PET-guided planning could reduce the radiation dose to nearby healthy structures such as the eyes and brainstem. The data show target volume reductions of 84% and critical structure dose reductions of 50% or more are achievable.
3. After surgery, do not assume that a clean MRI means no residual disease. PET detects residual tumor in 41–63% of patients considered fully resected. Discuss whether a postoperative baseline PET scan is appropriate.
4. For patients with recurrent or progressive meningiomas that no longer respond to surgery or radiation, ask about peptide receptor radionuclide therapy ([¹⁷⁷Lu]Lu-DOTATATE), which achieved disease stabilization in 60–80% of treated patients in the reviewed studies.
5. Interpret PET results with caution in asymptomatic patients. A positive scan does not automatically mean treatment is required; the risk of overtreatment is real, and shared decision-making with a multidisciplinary team is essential.

The authors emphasize that prospective multicenter trials with standardized protocols are essential to establish evidence-based clinical guidelines. Future research should focus on defining optimal SUVmax thresholds, standardizing acquisition and interpretation criteria, determining the ideal timing and frequency of surveillance scans, and validating next-generation [¹⁸F]SiTATE tracers against the established gallium-68 agents. Head-to-head comparisons among DOTATATE, DOTATOC, and DOTANOC would also help clinicians choose the right tracer for each clinical scenario.

Frequently Asked Questions

What is SSTR-targeted PET imaging and how does it work?

SSTR-targeted PET uses radioactive tracers that bind to somatostatin receptor subtype 2 (SSTR2), which meningiomas overexpress. The three most studied gallium-68 tracers are DOTATATE, DOTATOC, and DOTANOC. These bind SSTR2 with high affinity and are internalized by tumor cells, creating high tumor-to-background contrast. Gallium-68 has a 68-minute half-life and can be produced on-site with a generator, enabling widespread clinical use.

How sensitive is SSTR-targeted PET for detecting meningiomas?

Across reviewed studies, overall diagnostic sensitivity ranges from 95% to 100%, meaning the test rarely misses an actual meningioma. For bone involvement, one study of 82 patients found PET/CT achieved 98.5% sensitivity versus 53.7% for MRI. In 13 ambiguous optic pathway lesions, PET correctly classified 10, outperforming conventional imaging. These results come from multiple studies, though many were retrospective and had small sample sizes.

Can SSTR-targeted PET change my treatment plan?

Yes. In a case series of 12 patients, PET altered clinical management in up to 42% of cases, leading to treatment plan modifications or identifying additional lesions, including subcentimeter and intraosseous disease not clearly visible on MRI or CT. PET can also help decide whether to operate, where to aim radiation, and how closely to monitor after therapy. However, the clinical significance of positive findings in asymptomatic patients remains unclear.

How does PET help plan radiation therapy for meningiomas?

In one study of 29 intermediate-risk patients, PET/MRI-guided planning reduced the mean target volume by 84% (from 71.39 to 11.12 cm³) and decreased radiation dose to critical structures by 50% or more, while maintaining complete tumor coverage. In 85 patients with cavernous sinus meningiomas, PET-guided radiotherapy raised 5-year progression-free survival from 55.7% to 100%. PET also enabled safer dose escalation, reducing ocular exposure from 45 Gy to 32 Gy.

After surgery, can PET detect residual tumor that MRI misses?

Yes. In 37 patients classified as fully resected by Simpson grading and postoperative MRI, PET detected tumor remnants in 41–63% of patients, many not visible on MRI. This challenges the assumption that a Simpson Grade I–II resection plus a clean MRI means no tumor remains. A negative PET scan is strongly associated with favorable outcomes and low recurrence risk, but the optimal timing and frequency of follow-up scans are not well-defined.

What are the limitations or risks of SSTR-targeted PET?

Limitations include nonspecific SSTR uptake in other tissues, lower spatial resolution than MRI, and no standardized SUVmax thresholds (published cutoffs range from 2.3 to greater than 4.0). The clinical significance of positive findings in asymptomatic patients is unresolved, and there is a real risk of overtreatment if every PET finding triggers aggressive therapy. Optimal timing and frequency of surveillance scans also remain undefined.

What is peptide receptor radionuclide therapy (PRRT) for meningiomas?

PRRT is a theranostic approach using the same molecular target for imaging and therapy. Diagnostic tracers reveal where SSTR2 is present; then a therapeutic partner, [¹⁷⁷Lu]Lu-DOTATATE, carries radioactive lutetium-177 directly to those receptors, delivering targeted radiation from inside tumor cells. In 15 patients with progressive, treatment-refractory meningiomas, disease stabilization occurred in 60–80% of cases. Long-term toxicity and durability of responses remain under investigation.

When should a patient with a meningioma seek a second opinion on their diagnosis or treatment plan?

Consider a second opinion when MRI findings are ambiguous, especially for tumors at the skull base, in the cavernous sinus, or along the optic pathway, or when bone involvement is suspected. SSTR-targeted PET detects bone involvement in 98.5% of cases versus 53.7% for MRI, and changes management in up to 42% of cases. After apparent complete removal, PET finds residual tumor in 41–63% of patients that MRI missed. A second opinion can clarify whether PET-guided planning or surveillance is appropriate. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Somatostatin receptor PET in meningioma: diagnosis, therapy, and surveillance.

Authors: Gujral J, Gandhi OH, Amanullah AA, Singh SB, Ayubcha C, Patil S, Werner TJ, Revheim ME, Brem S, Alavi A.

Journal: Nuclear Medicine Communications, 2026, Volume 47, pages 491–502. Published by Wolters Kluwer Health, Inc.

DOI: 10.1097/MNM.0000000000002122

Received: December 5, 2025; Accepted: January 30, 2026.

This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace individualized medical advice from a qualified healthcare provider.